ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • RCT and rheumatoid arthritis
  • RCT and scleroderma
  • RCT and systemic sclerosis
  • RCT and vasculitis
  • rdw
  • reactions
  • reactions and systemic lupus erythematosus (SLE)
  • reactivation and Trypanosoma Cruzi
  • Reactive arthritis
  • reactive arthritis and infection
  • reactive arthritis and metabolomics
  • Reactive arthritis and rheumatic disease
  • reactive arthritis and spondylarthritis
  • Reactive arthritis and spondylarthropathy
  • reactive arthritis and synovial fluid
  • reactive oxygen species
  • Reactogenicity
  • readability and internet
  • readmission
  • readmission rate and quality improvement
  • real life and coventry
  • Real World Evidence
  • real world evidence and claims database study
  • real-world
  • Real-World Evidence and AWARE
  • Real-world study
  • Receptor for Advanced Glycation Endproducts
  • receptors and rheumatoid arthritis (RA)
  • recommendation
  • recruiting
  • recruitment
  • recruitment and rheumatoid arthritis (RA)
  • recruitment and self-management
  • recruitment and social media
  • recruitment and strategic planning
  • recruitment and systemic sclerosis
  • recruitment and tai chi
  • recruitment and Workforce
  • Recurrent fracture
  • Recurrent fracture and osteoporosis
  • Recurrent Polychondritis
  • Redox Balance
  • Redox Balance and animal models
  • Referrals
  • Referrals and axial spondyloarthritis
  • Referrals and digital technologies
  • Referrals and inflammatory arthritis
  • Referrals and quality improvement
  • Referrals and rheumatoid arthritis (RA)
  • Referrals and spondylarthritis
  • Referrals and strategic planning
  • Referrals and Triage
  • Reflex Sympathetic Dystrophy and economics
  • regeneration
  • regeneration and risk assessment
  • regeneration and stem cells
  • regeneration and synovial cells
  • regional difference
  • registries
  • registries and Elderly
  • registries and registry
  • registries and rheumatic disease
  • registries and rheumatoid arthritis (RA)
  • registries and rheumatologic practice
  • registries and rituximab
  • registries and safety
  • registries and spondylarthropathy
  • Registries and statistical methods
  • registries and systemic lupus erythematosus (SLE)
  • Registries and systemic sclerosis
  • registries and treatment
  • registry
  • registry and epidemiologic methods
  • registry and remission
  • registry and research methods
  • registry and rheumatic disease
  • registry and rheumatoid arthritis
  • registry and rheumatoid arthritis (RA)
  • registry and risk assessment
  • registry and safety
  • registry and sarcoidosis
  • registry and scleroderma
  • registry and skin
  • registry and social media
  • registry and spine involvement
  • registry and spondylarthritis
  • registry and spondylarthropathy
  • registry and systemic lupus erythematosus (SLE)
  • registry and tocilizumab
  • registry and tofacitinib
  • registry and treatment
  • registry and tuberculosis
  • registry and tumor necrosis factor (TNF)
  • registry and uveitis
  • regulatory and rheumatoid arthritis
  • Regulatory cells
  • regulatory cells and Elderly
  • regulatory cells and remission
  • regulatory cells and rheumatoid arthritis
  • regulatory cells and rheumatoid arthritis (RA)
  • regulatory cells and skin
  • regulatory cells and spondylarthropathy
  • regulatory cells and systemic lupus erythematosus (SLE)
  • regulatory cells and systemic sclerosis
  • regulatory cells and tolerance
  • regulatory cells and toll-like receptors
  • regulatory cells and transcription factor
  • regulatory cells and treatment
  • regulatory cells and vasculitis
  • regulatory T cell
  • regulatory T cells and primary Sjögren’s syndrome
  • Rehabilitation
  • rehabilitation and activities of daily living (ADL)
  • rehabilitation and inflammatory arthritis
  • rehabilitation and rheumatic disease
  • rehabilitation and rheumatoid arthritis (RA)
  • rehabilitation and self-management
  • rehabilitation and sleep disorders
  • rehabilitation and systemic lupus erythematosus (SLE)
  • rehabilitation and systemic sclerosis
  • rehabilitation and technology
  • rehabilitation and total joint replacement
  • rehabilitation and website
  • Reimbursement
  • reimbursement and rheumatoid arthritis (RA)
  • Reiter's syndrome
  • rejection
  • relaps and Predictor
  • relapsing polychondritis
  • Relational Ethics
  • relative and self-management
  • remission
  • remission and Biologic agents
  • remission and Disease Activity
  • remission and Electronic Health Record
  • remission and magnetic resonance imaging (MRI)
  • remission and outcome
  • remission and outcome measures
  • remission and Patient Satisfaction
  • remission and real-world evidence
  • remission and registries
  • remission and reimbursement
  • remission and rheumatoid arthritis
  • remission and rheumatoid arthritis (RA)
  • remission and safety
  • remission and sex bias
  • remission and skin
  • Remission and spondylarthritis
  • remission and steroids
  • remission and synovitis
  • remission and systemic lupus erythematosus (SLE)
  • remission and therapy
  • remission and tobacco use
  • remission and tocilizumab
  • Remission and tofacitinib
  • remission and tofacitnib
  • remission and transplantation
  • remission and treatment
  • remission and treatment guidlelines
  • remission and treatment options
  • remission and tumor necrosis factor (TNF)
  • remission and ultrasonography
  • remission and ultrasound
  • remission and uric acid
  • remission and vasculitis
  • Remission Induction
  • remission off therapy
  • remote
  • remote health care services
  • Renal
  • Renal disease
  • renal disease and cohort
  • renal disease and gastrointestinal complications
  • renal disease and glomerulonephritis
  • renal disease and Lung Disease
  • renal disease and rheumatoid arthritis (RA)
  • renal disease and ribonucleoprotein (RNP)
  • renal disease and risk assessment
  • renal disease and rituximab
  • renal disease and scleroderma
  • renal disease and scleroderma-like conditions
  • renal disease and SRI
  • renal disease and systemic lupus erythematosus (SLE)
  • renal disease and thrombosis
  • renal disease and tophaceous gout
  • renal disease and transplantation
  • renal disease and treatment
  • renal disease and uric acid
  • renal disease and vasculitis
  • representation and conference speakers
  • Reproductive Health
  • Reproductive Health and family planning
  • Reproductive Health and pregnancy
  • Reproductive Health and rheumatic disease
  • Reproductive Health and systemic lupus erythematosus (SLE)
  • Research
  • Research and Rheumatology
  • research funding and rheumatology
  • research funding and young investigators
  • research methods
  • First |
  • « Previous Page
  • 50
  • 51
  • 52
  • 53
  • 54
  • [55]
  • 56
  • 57
  • 58
  • 59
  • 60
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology